deltatrials
Completed PHASE1 NCT00017121

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma to the Lung

Sponsor: Alliance for Clinical Trials in Oncology

Conditions Melanoma (Skin) Metastatic Cancer
Interventions sargramostim
Updated 7 times since 2017 Last updated: Jul 1, 2016 Started: May 31, 2002 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This PHASE1 trial investigates Melanoma (Skin) and Metastatic Cancer and is currently completed. Alliance for Clinical Trials in Oncology leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alliance for Clinical Trials in Oncology
  • National Cancer Institute (NCI)
Data source: Alliance for Clinical Trials in Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adrian, United States, Aurora, United States, Bismarck, United States, Bloomington, United States, Bowling Green, United States, Burnsville, United States, Canton, United States, Carthage, United States, Cedar Rapids, United States, Coon Rapids, United States and 47 more location s